Fate Therapeutics

Product Candidates

FT825

FT825 is our most advanced CAR T-cell product candidate for the treatment of solid tumors, which is currently undergoing Phase 1 clinical investigation in collaboration with Ono Pharmaceutical. FT825 is an iPSC-derived, CAR T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, and is specifically designed to overcome challenges in treating solid tumors, such as breast, gastric, bladder, and lung cancers.

FT825

We are currently enrolling in a multi-center, Phase 1 clinical trial of FT825 for the treatment of advanced solid tumors (NCT06241456). The Phase 1 study is designed to assess the safety, tolerability, and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate, of a single dose of FT825 as monotherapy and in combination with monoclonal antibody therapy.

To find out more about our clinical trials click here.

MENU